Shares of Auris Medical Holding AG (NASDAQ:EARS) fell 7.2% on Tuesday . The stock traded as low as $3.81 and last traded at $3.84, with a volume of 73,836 shares changing hands. The stock had previously closed at $4.14.

Several research firms have recently weighed in on EARS. Zacks Investment Research raised Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a report on Tuesday, July 12th. Leerink Swann restated a “buy” rating and issued a $12.00 price target on shares of Auris Medical Holding AG in a research report on Wednesday, June 15th. Finally, Jefferies Group restated a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th.

The stock’s 50-day moving average is $3.97 and its 200 day moving average is $3.95. The company’s market cap is $149.77 million.

Auris Medical Holding AG (NASDAQ:EARS) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.04. During the same quarter in the previous year, the business posted ($0.28) earnings per share. On average, equities analysts expect that Auris Medical Holding AG will post ($1.01) earnings per share for the current fiscal year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.